Company news: Waggener, Cancer drugs come up short

Share this article:
PR and marketing firm Waggener Edstrom has taken over Munich-based Patzer PR. The new asset is one of Germany's top 15 healthcare communications agencies, according to Waggener, which will continue to use the Patzer PR brand name in the near future, but will ultimately be folded into the Waggener brand. The company said in a statement that this latest acquisition is part of a larger global push, which has also included a combination of purchases and increasing its partner role in agencies in Australia, India, Korea and South Africa. “This acquisition is a natural progression for our Munich office and global healthcare practice,” CEO Melissa Waggener Zorkin said in a statement.

Despite an “amazing discoveries” vibe at the American Society of Clinical Oncology conference, a recent poll by research group MDLinx showed that shortages were keeping 90% of polled oncologists from getting key medications. This is an increase from a third quarter poll in 2011 that showed 67% of polled oncologists said they were struggling to get medications. Doxorubicin, which is used to treat bladder, breast and lung cancers was among the hardest to get, followed by cytarabine, which is used to treat leukemia and methotrexate, which is used for some head and neck cancers. According to Reuters, the drug shortage situation has gotten so bad that Henry Ford Hospital in Detroit takes a daily inventory. In October, President Obama ordered drug companies to announce expected shortages. The FDA has been used these warnings to convince others to step in, reported Reuters, who noted the FDA says such signals and cajoling has prevented shortages of 128 drugs in the last six months.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.